Total Payments
$34,169
2024 Payments
$140.24
Companies
2
Transactions
27
Payment Breakdown by Category
Consulting$16,835 (49.3%)
Other$12,773 (37.4%)
Research$4,384 (12.8%)
Food & Beverage$177.36 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,835 | 8 | 49.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,773 | 11 | 37.4% |
| Unspecified | $4,384 | 6 | 12.8% |
| Food and Beverage | $177.36 | 2 | 0.5% |
Payments by Type
General
$29,785
21 transactions
Research
$4,384
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $32,125 | 26 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $2,044 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $140.24 | 1 | GENZYME CORPORATION ($140.24) |
| 2023 | $3,331 | 5 | SANOFI-AVENTIS U.S. LLC ($2,044) |
| 2022 | $4,033 | 3 | GENZYME CORPORATION ($4,033) |
| 2021 | $4,714 | 2 | GENZYME CORPORATION ($4,714) |
| 2020 | $13,556 | 7 | GENZYME CORPORATION ($13,556) |
| 2019 | $797.50 | 3 | GENZYME CORPORATION ($797.50) |
| 2018 | $4,473 | 3 | GENZYME CORPORATION ($4,473) |
| 2017 | $3,125 | 3 | GENZYME CORPORATION ($3,125) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/16/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $140.24 | General |
| 08/04/2023 | SANOFI-AVENTIS U.S. LLC | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,044.00 | General |
| Category: Genetic Disease | ||||||
| 03/16/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $37.12 | General |
| 02/22/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 02/22/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 02/22/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 10/07/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 09/27/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Consulting Fee | Cash or cash equivalent | $1,884.00 | General |
| Category: Genetic Disease | ||||||
| 06/30/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Consulting Fee | Cash or cash equivalent | $1,648.50 | General |
| Category: Genetic Disease | ||||||
| 06/24/2021 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $3,464.00 | General |
| 05/10/2021 | GENZYME CORPORATION | — | — | In-kind items and services | $1,250.00 | Research |
| Study: A Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | ||||||
| 09/17/2020 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $6,313.00 | General |
| 06/30/2020 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,221.00 | General |
| 06/30/2020 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $818.07 | General |
| 03/31/2020 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,467.08 | General |
| 03/31/2020 | GENZYME CORPORATION | — | — | In-kind items and services | $1,005.00 | Research |
| Study: Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | ||||||
| 03/31/2020 | GENZYME CORPORATION | — | — | In-kind items and services | $981.75 | Research |
| Study: Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | ||||||
| 03/31/2020 | GENZYME CORPORATION | — | — | In-kind items and services | $750.00 | Research |
| Study: Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | ||||||
| 12/31/2019 | GENZYME CORPORATION | GZ402665 (Drug) | — | In-kind items and services | $131.18 | Research |
| Study: Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | ||||||
| 09/30/2019 | GENZYME CORPORATION | GZ402665 (Drug) | — | In-kind items and services | $266.32 | Research |
| Study: Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | ||||||
| 02/04/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 12/31/2018 | GENZYME CORPORATION | GZ402665 (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $421.74 | General |
| 09/12/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $856.26 | General |
| 02/12/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,195.00 | General |
| 07/13/2017 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Consulting Fee | In-kind items and services | $852.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | GENZYME CORPORATION | $3,134 | 5 |
| A Prospective, Cross-Sectional Survey Study to Collect Natural History Data in Patients with Niemann-Pick B Disease | GENZYME CORPORATION | $1,250 | 1 |
About Margaret Mcgovern, MD, PHD
Margaret Mcgovern, MD, PHD is a Clinical Genetics (M.D.) healthcare provider based in Stony Brook, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821046947.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Margaret Mcgovern, MD, PHD has received a total of $34,169 in payments from pharmaceutical and medical device companies, with $140.24 received in 2024. These payments were reported across 27 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($16,835).
Ad
Practice Information
- Specialty Clinical Genetics (M.D.)
- Other Specialties Pediatrics
- Location Stony Brook, NY
- Active Since 05/04/2006
- Last Updated 08/02/2007
- Taxonomy Code 207SG0201X
- Entity Type Individual
- NPI Number 1821046947
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $7,576
- XENPOZYME (Biological) $7,327
- GZ402665 (Drug) $819.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.